{
    "organizations": [],
    "uuid": "adf16750674b1b2176306e728faff49326eb9c8a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-acorda-files-marketing-authorizati/brief-acorda-files-marketing-authorization-application-for-inbrija-idUSFWN1R80HB",
    "ord_in_thread": 0,
    "title": "BRIEF-Acorda Files Marketing Authorization Application For Inbrija",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26, 2018 / 11:51 AM / Updated 6 minutes ago BRIEF-Acorda Files Marketing Authorization Application For Inbrija Reuters Staff March 26 (Reuters) - Acorda Therapeutics Inc: * ACORDA FILES MARKETING AUTHORIZATION APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER) * ACORDA THERAPEUTICS INC - ‍ACORDA IS SEEKING MARKETING APPROVAL IN EUROPEAN UNION FOR INBRIJA​ * ACORDA THERAPEUTICS INC - ‍U.SFDA IS CURRENTLY REVIEWING A NEW DRUG APPLICATION FOR INBRIJA AND HAS SET AN ACTION DATE OF OCT 5, 2018 UNDER PDUFA​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-26T14:48:00.000+03:00",
    "crawled": "2018-03-26T15:03:47.105+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "updated",
        "minute",
        "ago",
        "file",
        "marketing",
        "authorization",
        "application",
        "inbrija",
        "reuters",
        "staff",
        "march",
        "reuters",
        "acorda",
        "therapeutic",
        "inc",
        "acorda",
        "file",
        "marketing",
        "authorization",
        "application",
        "levodopa",
        "inhalation",
        "powder",
        "acorda",
        "therapeutic",
        "inc",
        "seeking",
        "marketing",
        "approval",
        "european",
        "union",
        "acorda",
        "therapeutic",
        "inc",
        "currently",
        "reviewing",
        "new",
        "drug",
        "application",
        "inbrija",
        "set",
        "action",
        "date",
        "oct",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}